search

argenx NV ADR (ARGX)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today
Sep 25, 2026

Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today

This article analyzes the performance of argenx (NASDAQ: ARGX) over the last five years, noting its outperformance compared to the market with an average annual return of 26.19%. An investment of $100 in ARGX five years ago would now be worth $309.74, highlighting the significant impact of compounded returns on investment growth. The company currently holds a market capitalization of $59.17 billion.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish
2 Wall Street Analysts Think Argenx Can Soar More Than 40%. Here's Why They're Right.
Sep 21, 2026

2 Wall Street Analysts Think Argenx Can Soar More Than 40%. Here's Why They're Right.

Two Wall Street analysts from Wells Fargo and UBS predict that Argenx's share price could increase by over 40% in the next year, supported by the company's strong financial growth, accelerating revenue, and impressive earnings. Argenx's success with its Vyvgart franchise in treating multiple autoimmune diseases, including positive late-stage results for Vyvgart Hytrulo, underpins this bullish outlook, despite potential risks from reliance on a single product and broader market headwinds.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish